| Old Articles: <Older 4571-4580 Newer> |
|---|
 |
The Motley Fool
February 7, 2008
Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition.   |
The Motley Fool
February 6, 2008
Brian Lawler |
Neurocrine on the Upswing? Neurocrine Bioscience releases year-end numbers, and updates investors on the status of its top drugs. |
The Motley Fool
February 6, 2008
Brian Lawler |
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
The Motley Fool
February 5, 2008
Brian Orelli |
Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter. |
The Motley Fool
February 5, 2008
Brian Orelli |
Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S. |
The Motley Fool
February 4, 2008
Brian Lawler |
Disenchanted With Chantix The FDA issues a health advisory for Chantix, Pfizer's new non-nicotine stop-smoking treatment. |
The Motley Fool
February 4, 2008
Brian Lawler |
Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note. |
The Motley Fool
February 4, 2008
Kristin Graham |
Best International Stock: Syneron Medical A quick summary of Israeli medical device maker Syneron, a company that could keep you and your portfolio both looking young and healthy. |
The Motley Fool
February 4, 2008
Brian Lawler |
Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications. |
| <Older 4571-4580 Newer> Return to current articles. |
